Company intelligence / Profile preview
Celldex Therapeutics
Hampton, New Jersey, USAcelldex.com ↗
- Ownership
- Public · CLDX
- Employees
- ~186
- Development stage
- Phase 3
01
Overview
Celldex’s lead asset, barzolvolimab—a monoclonal antibody targeting the KIT receptor—has advanced to Phase 3 trials for chronic spontaneous urticaria and completed or ongoing Phase 2 studies in other mast cell-driven diseases. The company is also developing bispecific antibodies such as CDX‑622 and CDX‑585 for inflammatory diseases and oncology. Previous programs in oncology were discontinued after mixed results; current focus is on severe allergic/inflammatory conditions with significant unmet need.[5][6][10]
- Therapeutic areas
- GastroenterologyDermatology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodies[1][2][4][5]
- Industry
- Biotech
02
Drug pipeline
28 assets27 more assets in the full pipeline.
Request access →03
Partnerships
Past collaborations with Medarex, Inc.Strategic partnerships with academic institutions and research organizations noted historically but no major current pharma partners listed in recent disclosures.[3][4]
04
Financials
- Market cap
- $2.6B
- Total revenue
- $22K
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on Celldex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celldex Therapeutics.